knowledge -WSS

knowledge

author：focus 2025-08-26 01:32:38 - browse：43

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： H.R. 3 is the wrong path to lower drug costs

hotspot

explore

WSS

FDA advisers back CAR

FDA scientists endorse Pfizer/BioNTech Covid

How to ethically and practically extend health care to all

FDA scientists endorse Pfizer/BioNTech Covid

Medicare slashes safety net hospital payments by nearly $1 billion

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

hotspot

knowledge

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

'Null' research findings aren't empty of meaning. Let's publish them

ChatGPT in medicine: STAT answers readers' burning questions

EPA limits use of carcinogenic gas for sterilizing medical devices

Duchenne breakthrough therapy leaves behind pioneering families

Florida officials tell state schools to teach AP Psychology 'in its entirety'

ChatGPT in medicine: STAT answers readers' burning questions

2 officers injured in shooting in Orlando, police say

Guidelines to prevent youth baseball injuries need more muscle

UCLA team creates talking throat patch for voice disorders

leisure time

Late stage cancers on the rise after pandemic delayed screenings

UCLA team creates talking throat patch for voice disorders

Amid AI frenzy, a top HHS official's quest to create safeguards

'Null' research findings aren't empty of meaning. Let's publish them

How to save health care price transparency rules

First U.S. drug developed to treat liver disease MASH is approved

hotspot

hotspot

explore

focus